SGLT2 inhibitors predispose patients to euglycemic diabetic ketoacidosis through multiple mechanisms including promotion of glucagon secretion from pancreatic Î±-cells, decreased urinary excretion of ketone bodies, and creation of a carbohydrate starvation state despite normal glucose levels.